A delayed decision on Karyopharm’s selinexor is the pick of the bunch for July.
Both Ardelyx and Rhythm Pharmaceuticals are looking for phase III clinical wins to kick off filing discussions for pipeline leads.
Upcoming data could help Novartis broaden the reach of its heart failure drug Entresto, while Miragen awaits a key test of its microRNA approach.
Beigene seeks very good data in Waldenström's macroglobulinaemia, while Galapagos aims to extend filgotinib's reach.
Protagonist Therapeutics and Pfizer will soon get an idea of their respective chances in beta-thalassaemia and Duchenne muscular dystrophy.
Anaptysbio’s etokimab needs to beat Dupixent, while Retrophin takes aims at an underserved rare disease.
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.
Biogen needs a win with its Tecfidera follow-on, while Kalvista hopes to make HAE where Biocryst failed.
Chiasma hopes to be able to file its oral acromegaly therapy by year-end, and Novartis wants to shore up its MS franchise.